Boehringer Ingelheim launches RE-VECTO global program to capture data on Praxbind® ...

• Praxbind^® (idarucizumab) is the specific reversal agent for the oral anticoagulant Pradaxa^® (dabigatran)^1,2
• Praxbind^® is already available in over 5,000 hospitals worldwide and is approved in over 35 countries³
• RE-VECTO will provide insights into the diverse types of situations in which reversal of an anticoagulant is performed in clinical practice

(BUSINESS WIRE)-- Boehringer Ingelheim today announces its global RE-VECTO program for Praxbind^® (idarucizumab), the specific reversal agent for Pradaxa^® (dabigatran etexilate). ...

Source : http://me-newswire.net//news/18473/en...